Cell and Gene Therapy Insights Volume 11 Issue 3

Volume 11 Issue 3

Download PDF

Featuring

Issue Spotlight: Gene therapy analytics and CMC
Other articles
Webinars

Gene therapy analytics and CMC

Expert Insight

A structured approach to addressing leachable risk in cell and gene therapies

Jason Creasey

24 April

Read

Innovator Insight

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

Marc Struhalla, Svenja Michalek

26 March

Read

Viewpoint

A path toward universal agreement on fulfilling the need for rapid and reliable sterility assays in gene therapy

Qin Xiang

14 April

Read

Interview

Harnessing AI and omics for next-generation gene therapy manufacturing

Richard Braatz, Irene Rombel

14 April

Read

Advancing quality standards for gene therapies: a USP perspective

Fouad Atouf

8 April

Read

Journal articles

FastFacts

Essential equipment for advancing cell and gene therapy: innovations in incubation, monitoring, and cold storage

Tia Harmon

7 May

Read

A novel PCR-free hybridization method for titering gene therapy vectors in crude cell lysates and various in-process matrices

Wai Choi

4 April

Read

Interview

Overcoming translational challenges to advance cell therapy for neonatal brain injury

Mikey Creane

6 May

Read

Exploring translational challenges and strategies for advancing gene therapies in neurodegenerative diseases

Joseph Scarrott

17 April

Read

Exploring the challenges and innovations in CGT product commercialization

Ted Slocomb

14 April

Read

Advancing optogenetic therapies for retinal diseases: a regulatory vision

Ananta Ayyagari

24 March

Read

AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques

Andreja Livk, Sebastijan Peljhan

27 February

Watch

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

R Noel, G Hamblen, C Fenge

1 April

Watch

Strategies for streamlined manufacturing and analytics in CGT development

L Mueller, S Weber, D Windgassen

1 April

Watch

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

John Bowen, Brian Tomkowicz

2 April

Watch

Armor CAR T cells with enhanced potency for cancer immunotherapy

Saba Ghassemi

8 April

Watch

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Dan Oliver, Ji Hyun Lee

9 April

Watch

Achieving high-titer rAAV production with significantly reduced encapsidated host cell DNA

Ines Goncalves

10 April

Watch

Next-generation sequencing in adventitious agent testing: navigating regulatory acceptance

Olaf Stamm, Horst Ruppach

15 April

Watch

Manufacturing Quality Control for Plasmid DNA Critical Starting Materials

A Frazer, L R. Salvitti, S Lovatt et al.

29 April

Watch

Safety assays for quality control of ATMPs: improved mycoplasma detection for cell-based biotherapeutics

Jens Björkman, Andreas Hecker

30 April

Watch

CELL AND GENE THERAPY INSIGHTS

April 2025 Issue

Volume 11 Issue 3

Featuring

SPOTLIGHT

Gene therapy analytics and CMC

Expert Insight

A structured approach to addressing leachable risk in cell and gene therapies

Innovator Insight

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

Viewpoint

A path toward universal agreement on fulfilling the need for rapid and reliable sterility assays in gene therapy

Interview

Harnessing AI and omics for next-generation gene therapy manufacturing

Advancing quality standards for gene therapies: a USP perspective

Journal articles

FastFacts

Essential equipment for advancing cell and gene therapy: innovations in incubation, monitoring, and cold storage

A novel PCR-free hybridization method for titering gene therapy vectors in crude cell lysates and various in-process matrices

Interview

Overcoming translational challenges to advance cell therapy for neonatal brain injury

Exploring translational challenges and strategies for advancing gene therapies in neurodegenerative diseases

Exploring the challenges and innovations in CGT product commercialization

Advancing optogenetic therapies for retinal diseases: a regulatory vision

Webinars

AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Strategies for streamlined manufacturing and analytics in CGT development

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

Armor CAR T cells with enhanced potency for cancer immunotherapy

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Achieving high-titer rAAV production with significantly reduced encapsidated host cell DNA

Next-generation sequencing in adventitious agent testing: navigating regulatory acceptance

Manufacturing Quality Control for Plasmid DNA Critical Starting Materials

Safety assays for quality control of ATMPs: improved mycoplasma detection for cell-based biotherapeutics

CELL AND GENE THERAPY INSIGHTS

April 2025 Issue

Volume 11 Issue 3

Featuring

SPOTLIGHT

Gene therapy analytics and CMC

Expert Insight

A structured approach to addressing leachable risk in cell and gene therapies

Innovator Insight

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

Viewpoint

A path toward universal agreement on fulfilling the need for rapid and reliable sterility assays in gene therapy

Interview

Harnessing AI and omics for next-generation gene therapy manufacturing

Advancing quality standards for gene therapies: a USP perspective

Journal articles

FastFacts

Essential equipment for advancing cell and gene therapy: innovations in incubation, monitoring, and cold storage

A novel PCR-free hybridization method for titering gene therapy vectors in crude cell lysates and various in-process matrices

Interview

Overcoming translational challenges to advance cell therapy for neonatal brain injury

Exploring translational challenges and strategies for advancing gene therapies in neurodegenerative diseases

Exploring the challenges and innovations in CGT product commercialization

Advancing optogenetic therapies for retinal diseases: a regulatory vision

Webinars

AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Strategies for streamlined manufacturing and analytics in CGT development

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

Armor CAR T cells with enhanced potency for cancer immunotherapy

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Achieving high-titer rAAV production with significantly reduced encapsidated host cell DNA

Next-generation sequencing in adventitious agent testing: ﻿navigating regulatory acceptance

Manufacturing Quality Control for Plasmid DNA Critical Starting Materials

Safety assays for quality control of ATMPs: improved mycoplasma detection for cell-based biotherapeutics

Next-generation sequencing in adventitious agent testing: navigating regulatory acceptance